A medicine can cost less after Medicare negotiates its price. A generic can also bring down the cost over the same period. Franklin and colleagues used public drug-plan files to compare changes for selected cardiovascular drugs. The story is easiest to read with the comparison group in view.

THE SHORT READ
  • The analysis included 6,215 plans, comprising 5,738 Medicare Advantage plans and 477 stand-alone drug plans.
  • In the group without a generic option, the estimated extra reduction relative to the comparison group was $56.63 per 30 days. In the group with a newly available generic, it was $7.46.
  • The figures use plan rules for the initial coverage phase. Individual pharmacy bills and year-long spending would require different data.
THE STUDY AT A GLANCEMedicare price negotiation and generic availability · Franklin et al.
Paper date
19 November 2026
Plans included
6,215 Medicare drug coverage plans
Cost unit
US dollars per 30 days of medication
Policy period
First year of negotiated prices in 2026

Original publication: 19 Nov 2026 · The date above refers to this brief.

THE NUMBERS, IN CONTEXT

Estimated relative reductions in 30-day cost

US dollars per 30 days, reduction shown as a positive amount

No generic available56.63
Generic became available7.46
060
Magnitudes of the two difference-in-differences estimates. The confidence intervals and signs are in the comparison table.
THE EXPERIMENT, EXPLAINED

How the cost comparison works

  1. Estimate earlier costs

    Calculate an initial-coverage cost for each medication and plan.

  2. Estimate later costs

    Observe estimated costs after negotiated prices took effect.

  3. Use the comparator change

    Compare the change where prices were negotiated with the change in the comparison group.

Press-News diagram of the study design.

What a cost in the plan file represents

The researchers estimated the out-of-pocket cost of a 30-day supply under a drug plan’s coverage rules, for the initial coverage phase. Their dataset contains plan-level estimates. Observed pharmacy bills would require beneficiary records. The findings summarize a set of drugs and plans in the policy comparison.

Source 1 ↗

A worked example from the published table

The listed mean for empagliflozin went from $77.29 to $43.21, a drop of $34.08. The mean for the non-negotiated comparator row without a generic went from $76.52 to $99.35, an increase of $22.83. Subtracting that increase from the first change gives −$56.91. This arithmetic uses two rows of the table. The paper’s regression includes additional medication comparisons.

Source 1 ↗

Which other price changes were already happening?

The regression’s estimated extra reduction for negotiated drugs without a generic was $56.63 (95% CI $55.48 to $57.78). In the analysis where generic versions appeared, the estimated reduction was $7.46 (95% CI $6.05 to $8.78). In that second analysis, the comparison drug also became available as a generic and its reported mean cost fell. The relative estimate asks how much larger the change was in the negotiated group.

Source 1 ↗

What goes into an individual bill

The analyses used different sets of medicines. The two estimates describe how their estimated costs moved relative to their respective comparison drugs. A patient’s cost over time could also depend on the chosen plan, cost-sharing rules, coverage phase and use. The researchers studied a limited set of medicines in the first year of negotiated prices.

Source 1 ↗

What a follow-up could measure

Claims linked to enrolment could show how price changes translated into amounts paid by beneficiaries and whether fills changed. A longer time series could help separate changes at generic entry, negotiated price implementation and other coverage changes.

Source 1 ↗
TRACE THE EVIDENCE

Find what was compared before reading a price change

Primary journal research letter. Checked the data source, plan count, estimated 30-day costs, main table, regression comparison and limitations.

01Do the amounts describe pharmacy bills for individual people?

What was observed
The reported estimates come from the plan files and apply to initial coverage for 30 days.
Where the conclusion stops
Individual and annual costs would require other data.

Source 1 · Methods and Limitations

02Why compare groups with the same generic availability?

What was observed
A new generic can change costs in both the negotiated and comparison groups.
Where the conclusion stops
Each estimate depends on which drugs and cost changes were included.

Source 1 · Main table and Results

Numbers you can inspect

MeasureValue & unitOrigin & method
Plans included6215 plansReported All included Medicare drug coverage plans.
Source 1 · Results
Medicare Advantage5738 plansReported Medicare Advantage drug coverage plans in the analysis.
Source 1 · Results
Stand-alone drug coverage477 plansReported Stand-alone plans in the analysis.
Source 1 · Results
Empagliflozin mean before77.29 US dollars per 30 daysReported Selected unadjusted mean for a worked comparison.
Source 1 · Main table, generic not available
Empagliflozin mean after43.21 US dollars per 30 daysReported Selected unadjusted mean for a worked comparison.
Source 1 · Main table, generic not available
Comparator mean before76.52 US dollars per 30 daysReported Mean in the no-negotiation comparator row.
Source 1 · Main table, generic not available
Comparator mean after99.35 US dollars per 30 daysReported Mean in the no-negotiation comparator row.
Source 1 · Main table, generic not available
Two-row worked comparison-56.91 US dollars per 30 daysCalculated (43.21 − 77.29) − (99.35 − 76.52), using reported means.
Source 1 · Main table, generic not available
Estimated change, generic unavailable-56.63 US dollars per 30 daysReported Regression estimate, 95% CI −57.78 to −55.48.
Source 1 · Main table and Results
Estimated change, generic became available-7.46 US dollars per 30 daysReported Regression estimate, 95% CI −8.78 to −6.05.
Source 1 · Main table and Results

Compare the actual experiments

These studies answer different questions. Read the unit and endpoint before comparing results.

StudyUnit & settingReadoutInterpretation boundary
Different data for the cost and the care received

Source 1 · Methods and Limitations

Drug coverage plans and integrated care boardsModeled cost and NHS activity claimsA price measure and a service activity count answer different access questions.
Using a comparison group to interpret change

Source 1 · Methods, difference-in-differences

Plan cost rows and Texas Medicare county outcomesEstimated medication costs and weekly outcomesA change during a policy or event means more when the comparison is explicit.
Download evidence table (CSV)

The export includes claims, available numbers, methods and source locations. It contains our reading notes and published summaries; it is not raw participant data or an independent reanalysis.

Evidence update · 21 Nov 2026
First publication. Any calculations in this brief use reported figures. The reading notes identify possible follow-up questions. AI source check; no human editorial or clinical review.

CONNECT THE EVIDENCE

How much did estimated costs change relative to the comparison?

AnalysisEstimated change per 30 daysWhat was compared
Generic unavailable−$56.63 (95% CI −$57.78 to −$55.48)Negotiated versus non-negotiated medicines without a generic.
Generic became available−$7.46 (95% CI −$8.78 to −$6.05)The comparison also includes new generic availability.
Two-row arithmetic example−$56.91One negotiated drug and one comparator row. The full model uses other data as well.

Model estimates and 95% CIs are from the article’s table. The final row is Press-News arithmetic from selected means.

READER QUESTIONS

Your questions, answered

What does the $56.63 estimate represent?

It is the difference between changes in estimated plan costs for negotiated and comparison drugs in the analysis without a generic option.

Where does the $56.91 worked example come from?

Subtract the comparison-row increase of $22.83 from the $34.08 reduction, keeping the signs. The example gives −$56.91.

Does a 30-day estimate describe total annual spending?

The paper estimates 30-day costs for the initial coverage phase. Total spending would also depend on use, coverage and costs throughout the year.

What does the study show about taking medicines as prescribed?

The paper compared plan costs. A study of medication use would need beneficiary-level records or other measures of adherence.

LIMITATIONS

Limits of this interpretation

  • The data describe plan rules for an initial coverage phase. They do not track beneficiary-level bills or health outcomes.
  • The two models use different groups of drugs and one policy year. Concurrent changes in coverage could affect the estimates.
  • The worked example uses two published means. It omits other drugs included in the fitted regression.
SOURCE NOTES

Sources & transparency

  1. Franklin et al. (2026) — Medicare Price Negotiation, Generic Availability, and Out-of-Pocket Costs for Cardiac Medications

    Primary journal research letter. Checked the data source, plan count, estimated 30-day costs, main table, regression comparison and limitations. · Accessed 21 Nov 2026

    DOI: 10.1001/jamanetworkopen.2026.45071

Prepared and source-checked with AI for Press-news Team. The source notes identify the material available during preparation. The article received no human editorial or clinical review. The source list supports the reported results and the calculations shown.

Source check: AI source check — primary research and stated source limits

Clinical review: Not applicable to this educational guide

Suggest a correction